COPD Management Guidelines

Initial Treatment Approach

The American Thoracic Society recommends starting with a short-acting bronchodilator (SABA or SAMA) as needed for symptom relief in patients with low symptoms and low exacerbation risk 1
For patients with high symptoms and low exacerbation risk, the American College of Chest Physicians suggests starting with a long-acting bronchodilator (LABA or LAMA) 1, 3
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends evaluating effectiveness and considering switching to alternative class if inadequate response 1

Long-acting muscarinic antagonists (LAMAs) provide significant improvements in lung function, dyspnea, and health status, and are superior to LABAs in preventing exacerbations 2
The American College of Chest Physicians recommends LAMAs as first-line monotherapy due to their superior efficacy in reducing exacerbations compared to LABAs 2

Inhaled corticosteroids (ICS) are not recommended as first-line monotherapy in COPD, and should be reserved for patients with a history of exacerbations despite appropriate treatment with long-acting bronchodilators 1, 3
ICS use increases the risk of pneumonia, especially in current smokers, older patients, and those with prior pneumonia 3
Short-acting bronchodilators are recommended as rescue medication for immediate symptom relief 1, 2

Smoking cessation is essential for all current smokers and can achieve long-term quit success rates of up to 25% with proper resources 2
Pulmonary rehabilitation is recommended for patients with high symptom burden (Groups B, C, and D) 1, 3
Vaccination against influenza and pneumococcal disease is recommended for all COPD patients 2